



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross and Blue Shield Association

Medical Policy

Scintimammography and Gamma Imaging of the Breast and Axilla

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 494

BCBSA Reference Number: 6.01.18

NCD/LCD: N/A

Related Policies

None

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are **INVESTIGATIONAL** in all applications, including, but not limited to their use as an adjunct to mammography or in staging the axillary lymph nodes.

Use of gamma detection following radiopharmaceutical administration for localization of sentinel lymph nodes in patients with breast cancer may be considered **MEDICALLY NECESSARY**.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO Blue SM	Prior authorization is not required .
Medicare PPO Blue SM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
78800	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area
78801	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas

HCPCS Codes

HCPCS codes:	Code Description
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose

The following HCPCS code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

HCPCS Codes

HCPCS codes:	Code Description
S8080	Scintimammography (radioimmunoscintigraphy of the breast), unilateral, including supply of radiopharmaceutical

DESCRIPTION

MAMMOGRAPHY

Mammography is the main screening modality for breast cancer, despite its limitations in terms of less than ideal sensitivity and specificity. Limitations of mammography are a particular issue for women at high risk of breast cancer, for whom cancer risk exceeds the inconvenience of more frequent screening, starting at a younger age, with more frequent false-positive results. Furthermore, the sensitivity of mammography is lower in women with radiographically dense breasts, which is more common among younger women. The clinical utility of adjunctive screening tests is primarily in the evaluation of women with inconclusive results on mammography. A biopsy is generally performed on a breast lesion if imaging cannot rule out malignancy with certainty. Therefore, adjunctive tests will be most useful in women with inconclusive mammograms if they have a high negative predictive value and can preclude the need for biopsy. Additional imaging for asymptomatic women who have dense breasts and negative mammograms has been suggested, but the best approach is subject to debate (see the TEC Special Report [2013]¹).

SCINTIMAMMOGRAPHY

Scintimammography is a diagnostic modality using radiopharmaceuticals to detect breast tumors. After intravenous injection of a radiopharmaceutical, the breast is evaluated using planar imaging. Scintimammography is performed with the patient lying prone, and the camera positioned laterally, which increases the distance between the breast and the camera. Special camera positioning to include the

axilla may be included when the area of interest is an evaluation for axillary metastases. Scintimammography using conventional imaging modalities has relatively poor sensitivity in detecting smaller lesions (eg, <15 mm), because of the relatively poor resolution of conventional gamma cameras in imaging the breast.

BREAST-SPECIFIC GAMMA IMAGING

Breast-specific gamma imaging (BSGI) and molecular breast imaging (MBI) were developed to address the poor resolution of conventional gamma cameras. Breast-specific gamma cameras acquire images while the patient is seated in a position similar to that in mammography and the breast is lightly compressed. Detector heads are immediately next to the breast, increasing resolution, and images can be compared with mammographic images. BSGI and MBI differ primarily in the number and type of detectors used (eg, multicrystal arrays of cesium iodide or sodium iodide, or nonscintillating, semiconductor materials, such as cadmium zinc telluride). In some configurations, a detector is placed on each side of the breast and used to compress it lightly. The maximum distance between the detector and the breast is therefore from the surface to the midpoint of the breast. The radiotracer typically used is technetium 99m (Tc 99m) sestamibi, and MBI takes approximately 40 minutes.²

LYMPHOSCINTIGRAPHY AND HAND-HELD GAMMA DETECTION

Preoperative lymphoscintigraphy and/or intraoperative hand-held gamma detection of sentinel lymph nodes is a method of identifying sentinel lymph nodes for biopsy after radiotracer injection. Surgical removal of one or more sentinel lymph nodes is an alternative to full axillary lymph node dissection for staging evaluation and management of breast cancer. Several trials have compared outcomes following sentinel lymph node biopsy with axillary lymph node dissection for managing patients who have breast cancer. The National Surgical Adjuvant Breast and Bowel Project trial B-32 examined whether sentinel lymph node dissection provides similar survival and regional control as full axillary lymph node dissection in the surgical staging and management of patients with clinically invasive breast cancer. This multicenter randomized controlled trial included 5611 women and observed statistically similar results for overall survival, disease-free survival, and regional control based on 8-year Kaplan-Meier estimates.³ Additional 3-year follow-up of morbidity after surgical node dissection revealed lower morbidity in the sentinel lymph node dissection group, including lower rates of arm swelling, numbness, tingling, and fewer early shoulder abduction deficits.⁴ A recent systematic review and meta-analysis by Ram et al (2014) reported no significant difference in overall survival (hazard ratio, 0.94; 95% confidence interval, 0.79 to 1.19), no significant difference in disease-free survival (hazard ratio, 0.83; 95% confidence interval, 0.60 to 1.14), and similar rates of locoregional recurrence.⁵ However, axillary node dissection was associated with significantly greater surgical morbidity (eg, wound infection, arm swelling, motor neuropathy, numbness) than sentinel node biopsy.

RADIOPHARMACEUTICALS

Scintimammography, BSGI, and MBI

The primary radiopharmaceutical used with BSGI or MBI is Tc 99m sestamibi. The product label states that Tc 99m sestamibi is “indicated for planar imaging as a second-line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Technetium Tc-99m sestamibi is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.”⁶

Technetium TC-99m tetrofosmin (Myoview™), a gamma-emitter used in some BSGI studies,^{7,8} is approved by the Food and Drug Administration (FDA) only for cardiac imaging.⁹

Lymphoscintigraphy and/or Hand-Held Gamma Detection

The primary radiopharmaceuticals used for lymphoscintigraphy include Tc 99m pertechnetate–labeled colloids and Tc 99m tilmanocept (Lymphoseek).¹⁰ Whereas, Tc 99m sulfur colloid may frequently be used for intraoperative injection and detection of sentinel lymph nodes using hand-held gamma detection probe.

RADIATION EXPOSURE

Scintimammography, BSGI, and MBI

The radiation dose associated with BSGI is substantial for diagnostic breast imaging modalities.

According to Appropriateness Criteria from American College of Radiology, the radiation dose from BSGI is 10 to 30 mSv, which is 15 to 30 times higher than the dose from a digital mammogram.¹¹ According to the American College of Radiology, at these levels, BSGI is not indicated for breast cancer screening.

According to a study by Hruska and O'Connor (2015; who reported receiving royalties from licensed technologies by an agreement with Mayo Clinic and Gamma Medica), the effective dose from a lower "off-label" administered dose of 240 to 300 MBq (6.5-8 mCi) of Tc 99m sestamibi that is made feasible with newer dual-head MBI systems, is 2.0 to 2.5 mSv. For comparison, the effective dose (ie, mean glandular dose) of digital mammography is estimated to be about 0.5 mSv.¹² However, it is important to note that the dose for MBI is given to the entire body. The authors compared this dose with the estimated annual background radiation, which varies worldwide between 2.5 mSv and 10 mSv, and asserted that the effective dose from MBI "is considered safe for use in routine screening."

Hendrick (2010) calculated mean glandular doses and lifetime attributable risks of cancer, due to film mammography, digital mammography, BSGI, and positron emission mammography (PEM).¹³ The author, a consultant to GE Healthcare and a member of the medical advisory boards of Koning (manufacturer of dedicated breast computed tomography) and Bracco (magnetic resonance contrast agents), used group risk estimates from the Biological Effects of Ionizing Radiation VII report¹⁴ to assess the risk of radiation-induced cancer and mortality from breast imaging studies. For a patient with average-sized breasts (compressed thickness during mammography of 5.3 cm per breast), estimated lifetime attributable risks of cancer at age 40 were:

- 5 per 100,000 for digital mammography (breast cancer only),
- 7 per 100,000 for screen-film mammography (breast cancer only),
- 55 to 82 per 100,000 for BSGI (depending on the dose of Tc 99m sestamibi), and
- 75 for 100,000 for PEM.
- Corresponding lifetime attributable risks of cancer mortality at age 40 were:
- 1.3 per 100,000 for digital mammography (breast cancer only),
- 1.7 per 100,000 for screen film mammography (breast cancer only),
- 26 to 39 per 100,000 for BSGI, and
- 31 for 100,000 for PEM.

A major difference in the impact of radiation between mammography and BSGI or PEM is that, for mammography, the substantial radiation dose is limited to the breast. With BSGI and PEM, all organs are irradiated, increasing the risks associated with radiation exposure.

Notes: The term *molecular breast imaging* is used in different ways, sometimes for any type of breast imaging involving molecular imaging, including PEM, and sometimes it is used synonymously with the term *breast-specific gamma camera*, as used in this review.

Use of single-photon emission computed tomography and positron emission tomography of the breast are not addressed in this review.

Summary

Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) use radiotracers with nuclear medicine imaging as a diagnostic tool for abnormalities of the breast. These tests are distinguished by the use of differing gamma camera technology, which may improve diagnostic performance for detecting small lesions. BSGI uses a single-head breast-specific gamma camera and a compression device; whereas, MBI uses dual-head breast-specific gamma cameras that also produce breast compression. Preoperative lymphoscintigraphy and/or intraoperative hand-held gamma detection of sentinel lymph nodes is a method of identifying sentinel lymph nodes for biopsy after radiotracer

injection. Surgical removal of one or more sentinel lymph nodes is an alternative to full axillary lymph node dissection for staging evaluation and management of breast cancer.

Scintimammography, BSGI, and MBI for Diagnosis

For individuals who have dense breasts or high risk for breast cancer who receive scintimammography, BSGI, or MBI as an adjunct to mammography, the evidence includes diagnostic accuracy studies. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. Three prospective studies have assessed the incremental difference in diagnostic accuracy when BSGI or MBI is added to mammography in women at increased risk. Sensitivity was higher with combined BSGI or MBI and mammography, but specificity was lower. Studies of women at increased risk of breast cancer and negative mammograms found that a small number of additional cancers were detected, but the recall rate was relatively high. Studies tended to include women at different risk levels (eg, women with dense breasts and those with *BRCA1*). Moreover, any potential benefits need to be weighed against the potential risks of additional radiation exposure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have indeterminate or suspicious breast lesions who receive scintimammography, BSGI, or MBI, the evidence includes diagnostic accuracy studies. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. In the available studies, compared with biopsy, the negative predictive value of BSGI (or MBI) varied from 83% to 94%. Given the relative ease and diagnostic accuracy of the criterion standard of biopsy, coupled with the adverse consequences of missing a breast cancer, the negative predictive value of BSGI (or MBI) would have to be extremely high to alter treatment decisions. The evidence to date does not demonstrate this level of negative predictive value. Moreover, the value of BSGI in evaluating indeterminate or suspicious lesions must be compared with other modalities that would be used, such as spot views for diagnostic mammography. The evidence is insufficient to determine the effects of the technology on health outcomes.

Scintimammography and BSGI for Treatment

For individuals who have breast cancer undergoing detection of residual tumor after neoadjuvant therapy who receive scintimammography and BSGI, the evidence includes diagnostic accuracy studies and a meta-analysis. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. The meta-analysis of studies evaluating the accuracy of BSGI for detecting residual tumor after neoadjuvant therapy found a pooled sensitivity of 86% and a pooled specificity of 69%, compared with histopathologic analysis. No studies were identified that compared the diagnostic accuracy of BSGI with other imaging approaches, or that investigated the clinical utility of this potential application of BSGI. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have breast cancer undergoing surgical planning for breast-conserving therapy who receive scintimammography and BSGI, the evidence includes a retrospective observational study. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. In the retrospective study, results suggested that magnetic resonance imaging identified more patients than BSGI who were not appropriate candidates for breast-conserving therapy. Prospective comparative studies are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have breast cancer undergoing detection of axillary metastases who receive scintimammography and BSGI, the evidence includes diagnostic accuracy studies and systematic reviews of diagnostic accuracy studies. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. A meta-analysis of the available diagnostic accuracy studies found that the sensitivity and specificity of BSGI are not high enough for this technology to replace the current standard practice, surgical nodal dissection. The evidence is insufficient to determine the effects of the technology on health outcomes.

Radiopharmaceutical and Gamma Detection for Treatment

For individuals who have breast cancer undergoing sentinel lymph node biopsy for detection of axillary metastases who receive radiopharmaceutical and gamma detection for localization of sentinel lymph nodes, the evidence includes 3 studies and a meta-analysis. Relevant outcomes are overall survival, disease-specific survival, test validity, and treatment-related morbidity. A meta-analysis and 3 additional studies have provided evidence that using radiopharmaceutical and gamma detection for localization of sentinel lymph nodes yields high success rates in identifying sentinel lymph nodes; additionally, the diagnostic performance generally offers better detection rates with radiopharmaceutical than with alternative methods (eg, using only blue dye). The evidence has indicated that sentinel lymph node biopsy provides similar long-term outcomes as full axillary lymph node dissection for control of breast cancer and offers more favorable early results with reduced arm swelling and better quality of life. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
10/2018	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
10/2017	New references added from BCBSA National medical policy.
2/2017	BCBSA National medical policy review. New medically necessary indications described. Clarified coding information. Effective 2/1/2017.
7/2015	New references added from BCBSA National medical policy.
11/2014	BCBSA National medical policy review. New investigational indications described. Coding information clarified. Effective 10/1/2014.
7/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
9/2011	Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements.
7/2011	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
6/2011	BCBSA National medical policy review. Changes to policy statements.
10/2010	Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements.
9/2010	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
11/2009	BCBSA National medical policy review. No changes to policy statements.
9/2009	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
10/2008	Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements.
10/2008	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
9/2008	BCBSA National medical policy review. No changes to policy statements.
10/2007	Reviewed - Medical Policy Group - Urology and Obstetrics/Gynecology. No changes to policy statements.
9/2007	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
8/2007	BCBSA National medical policy review. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Special report: screening symptomatic women with dense breasts and normal mammograms for breast cancer. *TEC Assessments*. 2013;Volume 28:Tab 15.
2. O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. *Expert Rev Anticancer Ther*. Aug 2009;9(8):1073-1080. PMID 19671027
3. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol*. Oct 2010;11(10):927-933. PMID 20863759
4. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol*. Aug 1 2010;102(2):111-118. PMID 20648579
5. Ram R, Singh J, McCaig E. Sentinel node biopsy alone versus completion axillary node dissection in node positive breast cancer: systematic review and meta-analysis. *Int J Breast Cancer*. Nov 2014;2014:513780. PMID 25383226
6. Lantheus Medical Imaging. Cardiolite® kit for the preparation of technetium Tc99m sestamibi for injection. 2016; <http://www.cardiolite.com/healthcare-professionals/prescribing-info.asp>. Accessed July 26, 2018.
7. Hruska CB, O'Connor MK. Nuclear imaging of the breast: translating achievements in instrumentation into clinical use. *Med Phys*. May 2013;40(5):050901. PMID 23635248
8. Schillaci O, Spanu A, Danieli R, et al. Molecular breast imaging with gamma emitters. *Q J Nucl Med Mol Imaging*. Dec 2013;57(4):340-351. PMID 24322791
9. GE Healthcare. Myoview™ kit for the preparation of technetium Tc99m tetrofosmin for injection. 2011 May; http://www3.gehealthcare.com/~media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinical%20product%20info/myoview/gehealthcare_myoview-prescribing-information.pdf?Parent=%7B8676C68D-813E-43A2-BBB8-036FD061A97B%7D. Accessed July 26, 2018.
10. Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. *Semin Nucl Med*. Apr 2005;35(2):116-128. PMID 15765374
11. American College of Radiology (ACR). Appropriateness criteria®: breast cancer screening. 2016; <https://acsearch.acr.org/docs/70910/Narrative/>. Accessed July 26, 2018.
12. Hruska CB, O'Connor MK. Curies, and grays, and sieverts, oh my: a guide for discussing radiation dose and risk of molecular breast imaging. *J Am Coll Radiol*. Oct 2015;12(10):1103-1105. PMID 26435124
13. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. *Radiology*. Oct 2010;257(1):246-253. PMID 20736332
14. Health risks from exposure to low levels of ionizing radiation: BEIR VII, Phase 2. Washington, DC: National Research Council of the National Academies Press; 2006.
15. Food and Drug Administration (FDA). 510(k) Summary: Gamma Medica™ Instruments: LumaGEM Scintillation Camera (K993813). 2000; https://www.accessdata.fda.gov/cdrh_docs/pdf/K993813.pdf. Accessed July 26, 2018.
16. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera. *Technol Eval Cent Assess Program Exec Summ*. Jun 2013;28(2):1-4. PMID 23865107

17. Rhodes DJ, Hruska CB, Connors AL, et al. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. *AJR Am J Roentgenol.* Feb 2015;204(2):241-251. PMID 25615744
18. Rhodes DJ, Hruska CB, Phillips SW, et al. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. *Radiology.* Jan 2011;258(1):106-118. PMID 21045179
19. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. *Radiology.* Oct 2005;237(1):274-280. PMID 16126919
20. Shermis RB, Wilson KD, Doyle MT, et al. Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. *AJR Am J Roentgenol.* Aug 2016;207(2):450-457. PMID 27186635
21. Brem RF, Ruda RC, Yang JL, et al. Breast-specific gamma-imaging for the detection of mammographically occult breast cancer in women at increased risk. *J Nucl Med.* May 2016;57(5):678-684. PMID 26823569
22. Berrington de Gonzalez A, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. *J Natl Cancer Inst.* Feb 4 2009;101(3):205-209. PMID 19176458
23. Ernestos B, Nikolaos P, Koulis G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. *Int J Radiat Oncol Biol Phys.* Mar 15 2010;76(4):1199-1205. PMID 20206018
24. Cho MJ, Yang JH, Yu YB, et al. Validity of breast-specific gamma imaging for Breast Imaging Reporting and Data System 4 lesions on mammography and/or ultrasound. *Ann Surg Treat Res.* Apr 2016;90(4):194-200. PMID 27073789
25. Meissnitzer T, Seymer A, Keinrath P, et al. The added value of semiquantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3T MR Imaging. *Br J Radiol.* Apr 17 2015:20150147. PMID 25882690
26. Tan H, Jiang L, Gu Y, et al. Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer. *Ann Nucl Med.* Jan 2014;28(1):17-24. PMID 24142630
27. Spanu A, Sanna D, Chessa F, et al. The clinical impact of breast scintigraphy acquired with a breast specific gamma-camera (BSGC) in the diagnosis of breast cancer: incremental value versus mammography. *Int J Oncol.* Aug 2012;41(2):483-489. PMID 22641247
28. Hruska CB, Phillips SW, Whaley DH, et al. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. *AJR Am J Roentgenol.* Dec 2008;191(6):1805-1815. PMID 19020253
29. Spanu A, Chessa F, Meloni GB, et al. The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer. *Clin Nucl Med.* Nov 2008;33(11):739-742. PMID 18936602
30. Brem RF, Petrovitch I, Rapelyea JA, et al. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. *Breast J.* Sep-Oct 2007;13(5):465-469. PMID 17760667
31. Guo C, Zhang C, Liu J, et al. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis. *Nucl Med Commun.* Jul 2016;37(7):675-688. PMID 26974314
32. Lee HS, Ko BS, Ahn SH, et al. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res Treat.* May 2014;145(1):91-100. PMID 24671359
33. Edwards C, Williams S, McSwain AP, et al. Breast-specific gamma imaging influences surgical management in patients with breast cancer. *Breast J.* Sep-Oct 2013;19(5):512-519. PMID 23848225
34. Xu HB, Li L, Xu Q. Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression. *Nucl Med Commun.* Nov 2011;32(11):980-988. PMID 21956488
35. Taillefer R. The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. *Semin Nucl Med.* Jan 1999;29(1):16-40. PMID 9990681
36. Schillaci O, Scopinaro F, Spanu A, et al. Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintigraphy. *Int J Oncol.* Mar 2002;20(3):483-487. PMID 11836558

37. Spanu A, Dettori G, Nuvoli S, et al. (99m)Tc-tetrofosmin SPET in the detection of both primary breast cancer and axillary lymph node metastasis. *Eur J Nucl Med*. Dec 2001;28(12):1781-1794. PMID 11734916
38. Pesek S, Ashikaga T, Krag LE, et al. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. *World J Surg*. Sep 2012;36(9):2239-2251. PMID 22569745
39. van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. *Ann Surg Oncol*. Dec 2012;19(13):4104-4111. PMID 22752379
40. Johnson CB, Boneti C, Korourian S, et al. Intraoperative injection of subareolar or dermal radioisotope results in predictable identification of sentinel lymph nodes in breast cancer. *Ann Surg*. Oct 2011;254(4):612-618. PMID 21918427
41. Martin RC, 2nd, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. *Surgery*. Aug 2000;128(2):139-144. PMID 10922983
42. Unkart J, Wallace A. Use of lymphoscintigraphy with Tc-99m tilmanocept does not affect the number of nodes removed during sentinel node biopsy in breast cancer [abstract]. *J Nucl Med*. 2016;57(Suppl 2):615. PMID
43. Sun X, Liu JJ, Wang YS, et al. Roles of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer patients. *Jpn J Clin Oncol*. Aug 2010;40(8):722-725. PMID 20430775
44. Mathew MA, Saha AK, Saleem T, et al. Pre-operative lymphoscintigraphy before sentinel lymph node biopsy for breast cancer. *Breast*. Feb 2010;19(1):28-32. PMID 19913418
45. Goldsmith SJ, Parsons W, Guiberteau MJ, et al. SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. *J Nucl Med Technol*. Dec 2010;38(4):219-224. PMID 21057112
46. Committee on Practice Bulletins-Gynecology. Practice Bulletin Number 179: Breast cancer risk assessment and screening in average-risk women. *Obstet Gynecol*. Jul 2017;130(1):e1-e16. PMID 28644335
47. Moy L, Heller SL, Bailey L, et al. ACR Appropriateness Criteria(R) palpable breast masses. *J Am Coll Radiol*. May 2017;14(5S):S203-S224. PMID 28473077
48. American College of Radiology (ACR). Appropriateness criteria®: breast pain. 2016; <https://acsearch.acr.org/docs/3091546/Narrative/>. Accessed July 26, 2018.
49. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening in women at higher-than-average risk: Recommendations from the ACR. *J Am Coll Radiol*. Mar 2018;15(3 Pt A):408-414. PMID 29371086
50. Lyman GH, Somerfield MR, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. *J Oncol Pract*. Mar 2017;13(3):196-198. PMID 28118104
51. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 26, 2018.
52. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Version 2.2018. 2018; https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. Accessed July 26, 2018.